![Keith Ward](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Keith Ward
Vorstandsvorsitzender bei
InterveXion Therapeutics LLC
Profil
Keith W.
Ward is the founder of Kuria Therapeutics, Inc. (founded in 2022) and currently holds the position of President & Chief Executive Officer.
He is also the President & Chief Executive Officer at InterveXion Therapeutics LLC since 2019.
Dr. Ward has previously worked as the Director-Preclinical Drug Discovery at GlaxoSmithKline LLC.
He served as an Independent Director at Skye Bioscience, Inc. from 2021 to 2024.
From 2008 to 2011, he was the Global VP-Pharmaceutical Research & Development at Bausch & Lomb, Inc. Dr. Ward held the position of Chief Development Officer & Executive VP at Reata Pharmaceuticals, Inc. from 2011 to 2019.
He also served as the Chief Development Advisor at Unicycive Therapeutics, Inc. from 2020 to 2022.
Dr. Ward holds a doctorate degree from The University of North Carolina at Chapel Hill and an undergraduate degree from Northeast Louisiana University.
Aktive Positionen von Keith Ward
| Unternehmen | Position | Beginn |
|---|---|---|
InterveXion Therapeutics LLC
 InterveXion Therapeutics LLC Pharmaceuticals: MajorHealth Technology Develops drugs and antibody-based therapies | Vorstandsvorsitzender | 01.01.2019 |
Kuria Therapeutics, Inc.
 Kuria Therapeutics, Inc. BiotechnologyHealth Technology Develops novel ophthalmic and dermal therapeutics | Vorstandsvorsitzender | 01.02.2022 |
Ehemalige bekannte Positionen von Keith Ward
| Unternehmen | Position | Ende |
|---|---|---|
| SKYE BIOSCIENCE, INC. | Direktor/Vorstandsmitglied | 01.08.2024 |
| UNICYCIVE THERAPEUTICS, INC. | Corporate Officer/Principal | 01.07.2022 |
| REATA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.03.2019 |
Bausch & Lomb, Inc.
 Bausch & Lomb, Inc. Medical SpecialtiesHealth Technology Manufactures and supplies contact lenses | Corporate Officer/Principal | 01.06.2011 |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Corporate Officer/Principal | - |
Ausbildung von Keith Ward
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
46
Beziehungen ersten Grades
9
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
Bausch & Lomb, Inc.
Bausch & Lomb, Inc. Medical SpecialtiesHealth Technology Manufactures and supplies contact lenses | Health Technology |
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics which regulates cellular metabolism and inflammation in serious neurologic diseases | Health Technology |
The University of North Carolina at Chapel Hill
 The University of North Carolina at Chapel Hill Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
InterveXion Therapeutics LLC
InterveXion Therapeutics LLC Pharmaceuticals: MajorHealth Technology Develops drugs and antibody-based therapies | Health Technology |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Health Technology |
Northeast Louisiana University
 Northeast Louisiana University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Skye Bioscience, Inc.
 Skye Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets cannabinoid derivatives to treat ophthalmic disorders | Health Technology |
Unicycive Therapeutics, Inc.
 Unicycive Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutic drugs to treat kidney diseases | Health Technology |
Kuria Therapeutics, Inc.
Kuria Therapeutics, Inc. BiotechnologyHealth Technology Develops novel ophthalmic and dermal therapeutics | Health Technology |
Wählen Sie MarketScreener 
